| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| Targets |
HIV-1/2
|
|---|---|
| ln Vitro |
2',3'-Dideoxyadenosine suppresses HIV-1 and simian immunodeficiency virus (SIV) in MT-4 cells with EC50 values of 5.27 and 5.3 μM, respectively. In T-phase CEM cells, 2',3'-Dideoxyadenosine suppresses HIV-1 and HIV-2 with EC50 values of 4 μM and 8 μM, respectively. In Molt 4/C8 cells, 2',3'-Dideoxyadenosine suppresses HIV-1 and HIV-2 with EC50 values of 4 μM and 5.5 μM, respectively. HIV-1 and HIV-2 in C8166 cells are inhibited by 2',3'-Dideoxyadenosine, with EC50 values of 17 μM and 22 μM, respectively. With an EC50 of 24 μM, 2',3'-Dideoxyadenosine suppresses the murine sarcoma virus (MSV) in C3H/3T3 cells [1].
|
| Cell Assay |
Antiviral activity of the test compounds[1]
CEM, MT-4, Molt 4/clone 8 and C8166 cells were suspended at 250 000–350 000 cells per ml of culture medium and infected with approximately 100 CCID50 (1 CCID50 being the 50% cell culture infective dose) of HIV-1(IIIB) or HIV-2(ROD). Then, 100 μl of the infected cell suspensions was added to 200-μl-microtiterplate wells containing 100 μl of an appropriate dilution of the test compounds (i.e., 250, 100, 20, 4, 0.8, 0.16, 0.032, 0.006, 0.001 μM). The inhibitory effect of the test compounds on HIV-1-induced syncytium formation in CEM, Molt 4 and C8166 cells was examined on day 4 post-infection, and their inhibitory effect on the viability of HIV-infected MT-4 cells was examined on day 5 post-infection, as described previously. The 50% effective concentration (EC50) was determined as the compound concentration required to inhibit syncytium formation (CEM, Molt 4, C8166) or to reduce cell viability (MT-4) by 50%. The 50% cytostatic concentration (CC50) was defined as the compound concentration required to reduce cell viability or cell proliferation by 50%[1]. |
| Toxicity/Toxicokinetics |
Toxicity Data
Mouse(po): LD50: 5 gm/kg Mouse(sc): LD50: 1320 mg/kg |
| References | |
| Additional Infomation |
2',3'-dideoxyadenosine is an off-white powder. (NTP, 1992)
2',3'-dideoxyadenosine is a purine 2',3'-dideoxyribonucleoside in which the nucleobase component is specified as adenine. It has a role as an EC 4.6.1.1 (adenylate cyclase) inhibitor and an EC 3.5.4.4 (adenosine deaminase) inhibitor. It is a purine 2',3'-dideoxyribonucleoside and a member of adenosines. Dideoxyadenosine is a prodrug form of didanosine, a nucleoside reverse transcriptase inhibitor analog of adenosine. A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is an inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal side effect is nephrotoxicity. In vivo, dideoxyadenosine is rapidly metabolized to DIDANOSINE (ddI) by enzymatic deamination; ddI is then converted to dideoxyinosine monophosphate and ultimately to dideoxyadenosine triphosphate, the putative active metabolite. |
| Molecular Formula |
C10H13N5O2
|
|---|---|
| Molecular Weight |
235.25
|
| Exact Mass |
235.106
|
| Elemental Analysis |
C, 51.06; H, 5.57; N, 29.77; O, 13.60
|
| CAS # |
4097-22-7
|
| PubChem CID |
20039
|
| Appearance |
White to off-white solid powder
|
| Density |
1.8±0.1 g/cm3
|
| Boiling Point |
539.1±60.0 °C at 760 mmHg
|
| Melting Point |
181-184 °C(lit.)
|
| Flash Point |
279.9±32.9 °C
|
| Vapour Pressure |
0.0±1.5 mmHg at 25°C
|
| Index of Refraction |
1.822
|
| LogP |
-0.43
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
17
|
| Complexity |
279
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
O1[C@]([H])(C([H])([H])O[H])C([H])([H])C([H])([H])[C@]1([H])N1C([H])=NC2=C(N([H])[H])N=C([H])N=C12
|
| InChi Key |
WVXRAFOPTSTNLL-NKWVEPMBSA-N
|
| InChi Code |
InChI=1S/C10H13N5O2/c11-9-8-10(13-4-12-9)15(5-14-8)7-2-1-6(3-16)17-7/h4-7,16H,1-3H2,(H2,11,12,13)/t6-,7+/m0/s1
|
| Chemical Name |
[(2S,5R)-5-(6-aminopurin-9-yl)oxolan-2-yl]methanol
|
| Synonyms |
Dideoxyadenosine; NSC-98700; 2',3'-Dideoxyadenosine; 4097-22-7; dideoxyadenosine; ADENOSINE, 2',3'-DIDEOXY-; ddAdo; ((2S,5R)-5-(6-Amino-9H-purin-9-yl)tetrahydrofuran-2-yl)methanol; NSC-98700; NSC 98700; CCRIS 428; D2A; DDA; ddAdo; 2′,3′-Dideoxyadenosine ; NSC 98700
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~100 mg/mL (~425.10 mM)
DMSO : ~100 mg/mL (~425.10 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (8.84 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (8.84 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (8.84 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 14.29 mg/mL (60.75 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication (<60°C). |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.2508 mL | 21.2540 mL | 42.5080 mL | |
| 5 mM | 0.8502 mL | 4.2508 mL | 8.5016 mL | |
| 10 mM | 0.4251 mL | 2.1254 mL | 4.2508 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
